Clinical Trials
22 trialsNCT03914300 2026-06-01
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04284774 2026-05-27
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02152995 2026-04-13
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00381641 2025-03-28
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01709435 2023-12-22
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT02408887 2022-09-27
Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00625846 2020-02-26
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03002623 2018-12-21
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00104871 2018-12-19
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00085293 2018-11-29
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Phase 2 Completed
NCT00923247 2018-11-29
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01502410 2018-06-26
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01182285 2018-05-16
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01811212 2018-04-03
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00126568 2018-01-19
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00729157 2017-03-15
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00118248 2017-02-15
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01838642 2017-02-15
Ponatinib for Advanced Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00559949 2017-01-30
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
National Cancer Institute (NCI)
Phase 2 Completed
NCT00134043 2014-08-11
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098813 2014-05-28
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
National Cancer Institute (NCI)
Phase 2 Completed
NCT00251316 2013-02-04
Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed